AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home BIOCELL Article
PDF (23.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Article | Open Access

Melatonin Ameliorates Hippocampal Excitotoxicity and Neuroinflammation in Permanent MCAO by Targeting NMDA/AMPA Receptors and the NLRP3 Inflammasome via Nrf2/PPARγ/JNK/NF-κB Crosstalk

Abdullah Alattar1Reem Alshaman1Fawaz E. Alanazi1Yusuf S. Althobaiti2Ghareb M. Soliman3Waleed Salman Khubrni1Howaida S. Ali4Fawad Ali Shah5,6( )
Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia
Department of Pharmacology and Toxicology, College of Pharmacy, Addiction and Neuroscience Taif University, Taif, 21944, Saudi Arabia
Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia
Department of Pharmacology, Faculty of Medicine, University of Tabuk, Tabuk, 71491, Saudi Arabia
Swat College of Pharmaceutical Sciences (SCPS), Gogdara, Swat, 19200, Khyber Pakhtunkhwa, Pakistan
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, 44000, Pakistan
Show Author Information

Abstract

Objectives

Permanent middle cerebral artery occlusion (pMCAO) can lead to hippocampal damage through multiple linked pathways such as reactive oxidative stress (ROS), neuroinflammation mediated by NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), tumour necrosis factor-alpha (TNF-α), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and glutamate excitotoxicity involving N-methyl-D-aspartate receptor subunits 2a and 2b (NR2a/NR2b) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR/GluR1). The hippocampus, which is essential for memory and cognition, is at a substantial risk of ischemic degeneration. The aim of this study was to investigate the neuroprotective potential of melatonin in regulating these pathways.

Method

Male adult rats were subjected to pMCAO, and melatonin (5 mg/kg) was administered just prior to ischemia, while sham-operated animals underwent surgery without nylon insertion. Hippocampal samples were collected 24 h after ischemia,

Results

Hippocampal tissues showed NLRP3 inflammasome activation, increased TNF-α and p-NF-κB, and decreased peroxisome proliferator-activated receptor (PPARγ) after pMCAO. Melatonin-modulated ischemia-induced glutamatergic receptor subunits (NR2a, NR2b, GluR1) dysregulation, which possibly stimulated the prosurvival pathways and reduced collagen response-mediated protein (CRMP2) and its phosphorylation. Melatonin also modulated the expression of the postsynaptic protein (PSD95) and inhibited inflammatory cascades while upregulating antioxidant proteins. Further, melatonin reduced inflammation triggered by NLRP3, restored synaptic integrity, possibly by enhancing nuclear factor erythroid 2-related factor 2 (Nrf2) expression.

Conclusion

These results demonstrated the dual role of melatonin by protecting ischemic brain damage both as a modulator of excitotoxicity and neuroinflammation/oxidative stress.

References

【1】
【1】
 
 
BIOCELL
Article number: 8

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Alattar A, Alshaman R, Alanazi FE, et al. Melatonin Ameliorates Hippocampal Excitotoxicity and Neuroinflammation in Permanent MCAO by Targeting NMDA/AMPA Receptors and the NLRP3 Inflammasome via Nrf2/PPARγ/JNK/NF-κB Crosstalk. BIOCELL, 2026, 50(3): 8. https://doi.org/10.32604/biocell.2026.074865

1

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 20 October 2025
Accepted: 04 January 2026
Published: 23 March 2026
© The Author 2026.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.